- IMAAVY (nipocalimab-aahu) demonstrates superior sustained disease control over 24 weeks compared to other FcRn blockers.
- Statistically significant improvements observed in MG-ADL scores at multiple timepoints versus competitors.
- Biweekly dosing regimen provides a sustainable treatment schedule for generalized myasthenia gravis (gMG) patients.
Johnson & Johnson (JNJ, Financial) has announced new data from an indirect treatment comparison (ITC) revealing that IMAAVY™ (nipocalimab-aahu) provides superior sustained disease control in generalized myasthenia gravis (gMG) patients compared to other approved FcRn blockers. Over a 24-week period, IMAAVY demonstrated statistically significant improvements in MG-ADL scores, especially between Weeks 8-24 against one competitor and Weeks 10-14 against another.
The results strengthen IMAAVY's position in the market, particularly due to its broader approval for both anti-AChR and anti-MuSK antibody-positive patients aged 12 and older. Unlike cyclic therapies requiring symptom relapse before retreatment, IMAAVY offers a predictable biweekly dosing regimen, allowing for better treatment planning and sustained disease control.
IMAAVY's approval for a wide patient demographic in the U.S. increases its market potential. Johnson & Johnson has also submitted a Marketing Authorisation Application to the European Medicines Agency to expand its reach in the European market, further solidifying its strategic advantage.
